TN2015000529A1 - Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors - Google Patents
Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitorsInfo
- Publication number
- TN2015000529A1 TN2015000529A1 TN2015000529A TN2015000529A TN2015000529A1 TN 2015000529 A1 TN2015000529 A1 TN 2015000529A1 TN 2015000529 A TN2015000529 A TN 2015000529A TN 2015000529 A TN2015000529 A TN 2015000529A TN 2015000529 A1 TN2015000529 A1 TN 2015000529A1
- Authority
- TN
- Tunisia
- Prior art keywords
- sub
- compounds
- kinase inhibitors
- compounds useful
- carboxamide compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
Disclosed are compounds of Formula (1) wherein: the two dotted lines represent either two single or two double bonds; Q is: R<sub>1</sub> is F, Cl, CN, or CH<sub>3</sub>; R<sub>2</sub> is Cl or CH<sub>3</sub>; R<sub>3</sub> is C(CH<sub>3</sub>)<sub>2</sub>OH or CH<sub>2</sub>CH<sub>2</sub>OH; R<sub>a</sub> is H or CH<sub>3</sub>; each R<sub>6</sub> is independently F, Cl, CH<sub>3</sub>, and/or OCH<sub>3</sub>; and n is zero, l, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361839141P | 2013-06-25 | 2013-06-25 | |
PCT/US2014/043978 WO2014210085A1 (en) | 2013-06-25 | 2014-06-25 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
TN2015000529A1 true TN2015000529A1 (en) | 2017-04-06 |
Family
ID=51210830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TN2015000529A TN2015000529A1 (en) | 2013-06-25 | 2014-06-25 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors |
Country Status (31)
Country | Link |
---|---|
US (6) | US9334290B2 (en) |
EP (1) | EP3013814B1 (en) |
JP (1) | JP6353529B2 (en) |
KR (1) | KR102346508B1 (en) |
CN (1) | CN105358546B (en) |
AR (1) | AR096721A1 (en) |
AU (1) | AU2014302548B2 (en) |
BR (1) | BR112015030723A8 (en) |
CA (1) | CA2916500A1 (en) |
CL (1) | CL2015003635A1 (en) |
CY (1) | CY1119371T1 (en) |
DK (1) | DK3013814T3 (en) |
EA (1) | EA026729B1 (en) |
ES (1) | ES2636652T3 (en) |
HK (1) | HK1223359A1 (en) |
HR (1) | HRP20171031T1 (en) |
HU (1) | HUE034460T2 (en) |
IL (1) | IL243296B (en) |
LT (1) | LT3013814T (en) |
MA (1) | MA38648B1 (en) |
MY (1) | MY176631A (en) |
PE (1) | PE20160519A1 (en) |
PH (1) | PH12015502630A1 (en) |
PL (1) | PL3013814T3 (en) |
PT (1) | PT3013814T (en) |
RS (1) | RS56371B1 (en) |
SI (1) | SI3013814T1 (en) |
TN (1) | TN2015000529A1 (en) |
TW (1) | TWI648272B (en) |
UY (1) | UY35625A (en) |
WO (1) | WO2014210085A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201510028PA (en) | 2013-06-25 | 2016-01-28 | Bristol Myers Squibb Co | Carbazole carboxamide compounds useful as kinase inhibitors |
KR102514914B1 (en) * | 2014-10-24 | 2023-03-27 | 브리스톨-마이어스 스큅 컴퍼니 | Carbazole derivatives |
AR102426A1 (en) | 2014-10-24 | 2017-03-01 | Bristol Myers Squibb Co | INDOLCARBOXAMIDE COMPOUNDS AS BTK INHIBITORS |
CN107108555B (en) | 2014-10-24 | 2020-12-01 | 百时美施贵宝公司 | Tricyclic atropisomer compounds |
CA3029482A1 (en) | 2016-07-01 | 2018-01-04 | Brio Device Llc | Intubation stylet with video feed |
CN108101905A (en) * | 2016-11-24 | 2018-06-01 | 中国科学院上海药物研究所 | Pyrimido [5,4-b] indolizine or pyrimido [5,4-b] pyrrole biopterin compound, preparation method and the usage |
CN110545826A (en) | 2016-12-03 | 2019-12-06 | 朱诺治疗学股份有限公司 | Methods and compositions for using therapeutic T cells in combination with kinase inhibitors |
JP7028889B2 (en) * | 2016-12-20 | 2022-03-02 | ブリストル-マイヤーズ スクイブ カンパニー | Method for Producing Tetrahydrocarbazole Carboxamide Compound |
WO2019208805A1 (en) | 2018-04-27 | 2019-10-31 | 小野薬品工業株式会社 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT |
CA3108065A1 (en) | 2018-07-31 | 2020-02-06 | Loxo Oncology, Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide |
WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
WO2022212893A1 (en) | 2021-04-02 | 2022-10-06 | Biogen Ma Inc. | Combination treatment methods of multiple sclerosis |
WO2023156311A1 (en) * | 2022-02-15 | 2023-08-24 | F. Hoffmann-La Roche Ag | Processes for the preparation of 1,2,3,5,6,7-hexahydro-s-indacene derivatives |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
CA2140722A1 (en) | 1994-01-24 | 1995-07-25 | Joseph A. Jakubowski | Beta-carboline thromboxane synthase inhibitors |
WO2005014599A1 (en) | 2003-06-04 | 2005-02-17 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds |
WO2005005429A1 (en) | 2003-06-30 | 2005-01-20 | Cellular Genomics, Inc. | Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds |
US20050288295A1 (en) | 2003-11-11 | 2005-12-29 | Currie Kevin S | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof |
WO2006044687A2 (en) | 2004-10-15 | 2006-04-27 | Takeda San Diego, Inc. | Kinase inhibitors |
MX2007005643A (en) | 2004-11-10 | 2008-03-13 | Cgi Pharmaceuticals Inc | Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity. |
MX2007007345A (en) | 2004-12-17 | 2007-09-07 | Glenmark Pharmaceuticals Sa | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders. |
TW200716551A (en) | 2005-03-10 | 2007-05-01 | Cgi Pharmaceuticals Inc | Certain substituted amides, method of making, and method of use thereof |
JP2009508872A (en) | 2005-09-16 | 2009-03-05 | セレネックス, インコーポレイテッド | Carbazole derivatives |
US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
CA2630562C (en) | 2005-11-22 | 2013-12-31 | Merck & Co., Inc. | Tricyclic compounds useful as inhibitors of kinases |
US20100160292A1 (en) | 2006-09-11 | 2010-06-24 | Cgi Pharmaceuticals, Inc | Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors |
WO2008032171A1 (en) | 2006-09-11 | 2008-03-20 | Matrix Laboratories Ltd. | Dibenzofuran derivatives as inhibitors of pde-4 and pde-10 |
US20090062251A1 (en) | 2007-08-17 | 2009-03-05 | Astrazeneca Ab | Novel Compounds 002 |
AU2008335761B2 (en) | 2007-12-13 | 2014-04-24 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
PL2247558T3 (en) | 2008-02-14 | 2022-05-02 | Eli Lilly And Company | Novel imaging agents for detecting neurological dysfunction |
GB0809360D0 (en) | 2008-05-22 | 2008-07-02 | Isis Innovation | Calcium modulation |
EP2151441A1 (en) | 2008-08-06 | 2010-02-10 | Julius-Maximilians-Universität Würzburg | Beta-carbolin-derivates as substrates for an enzyme |
JP5487214B2 (en) * | 2008-12-19 | 2014-05-07 | ブリストル−マイヤーズ スクイブ カンパニー | Carbazole carboxamide compounds useful as kinase inhibitors |
CN101475571B (en) | 2009-01-21 | 2011-06-22 | 中国药科大学 | Beta-carbolines cell cycle protein related kinase 2 inhibitor and use thereof |
US8242260B2 (en) | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
AU2011232058B2 (en) | 2010-03-26 | 2016-09-08 | Merck Patent Gmbh | Benzonaphthyridinamines as autotaxin inhibitors |
EP2582668B1 (en) * | 2010-06-16 | 2016-01-13 | Bristol-Myers Squibb Company | Carboline carboxamide compounds useful as kinase inhibitors |
EP2455378A1 (en) | 2010-11-03 | 2012-05-23 | Philip Morris Products S.A. | Carbazole and carboline derivatives, and preparation and therapeutic applications thereof |
BR112013011991A2 (en) | 2010-11-15 | 2016-08-30 | Viiv Healthcare Uk Ltd | compound, pharmaceutical composition, use of a compound, treatment method, product, and kit. |
CN103582637B (en) | 2011-05-17 | 2015-08-12 | 弗·哈夫曼-拉罗切有限公司 | Tyrosine kinase inhibitor |
WO2013054185A1 (en) | 2011-10-13 | 2013-04-18 | Pfizer, Inc. | Pyrimidine and pyridine derivatives useful in therapy |
-
2014
- 2014-06-24 TW TW103121681A patent/TWI648272B/en not_active IP Right Cessation
- 2014-06-24 UY UY0001035625A patent/UY35625A/en unknown
- 2014-06-24 AR ARP140102388A patent/AR096721A1/en unknown
- 2014-06-25 PE PE2015002665A patent/PE20160519A1/en active IP Right Grant
- 2014-06-25 EP EP14740094.9A patent/EP3013814B1/en active Active
- 2014-06-25 TN TN2015000529A patent/TN2015000529A1/en unknown
- 2014-06-25 EA EA201592287A patent/EA026729B1/en not_active IP Right Cessation
- 2014-06-25 BR BR112015030723A patent/BR112015030723A8/en not_active Application Discontinuation
- 2014-06-25 DK DK14740094.9T patent/DK3013814T3/en active
- 2014-06-25 WO PCT/US2014/043978 patent/WO2014210085A1/en active Application Filing
- 2014-06-25 SI SI201430268T patent/SI3013814T1/en unknown
- 2014-06-25 LT LTEP14740094.9T patent/LT3013814T/en unknown
- 2014-06-25 MY MYPI2015704738A patent/MY176631A/en unknown
- 2014-06-25 HU HUE14740094A patent/HUE034460T2/en unknown
- 2014-06-25 ES ES14740094.9T patent/ES2636652T3/en active Active
- 2014-06-25 PL PL14740094T patent/PL3013814T3/en unknown
- 2014-06-25 CN CN201480035611.8A patent/CN105358546B/en active Active
- 2014-06-25 PT PT147400949T patent/PT3013814T/en unknown
- 2014-06-25 US US14/314,602 patent/US9334290B2/en active Active
- 2014-06-25 AU AU2014302548A patent/AU2014302548B2/en not_active Ceased
- 2014-06-25 MA MA38648A patent/MA38648B1/en unknown
- 2014-06-25 RS RS20170904A patent/RS56371B1/en unknown
- 2014-06-25 JP JP2016523869A patent/JP6353529B2/en active Active
- 2014-06-25 CA CA2916500A patent/CA2916500A1/en not_active Abandoned
- 2014-06-25 KR KR1020167001632A patent/KR102346508B1/en active IP Right Grant
-
2015
- 2015-11-26 PH PH12015502630A patent/PH12015502630A1/en unknown
- 2015-12-15 CL CL2015003635A patent/CL2015003635A1/en unknown
- 2015-12-22 IL IL243296A patent/IL243296B/en active IP Right Grant
-
2016
- 2016-03-11 US US15/067,915 patent/US20160194338A1/en not_active Abandoned
- 2016-10-04 HK HK16111549.5A patent/HK1223359A1/en not_active IP Right Cessation
-
2017
- 2017-06-16 US US15/625,417 patent/US9850258B2/en active Active
- 2017-07-05 HR HRP20171031TT patent/HRP20171031T1/en unknown
- 2017-09-06 CY CY20171100943T patent/CY1119371T1/en unknown
- 2017-11-10 US US15/809,437 patent/US10106559B2/en active Active
-
2018
- 2018-09-25 US US16/140,750 patent/US10435415B2/en active Active
-
2019
- 2019-08-22 US US16/547,675 patent/US20190382416A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2015000529A1 (en) | Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors | |
PH12020500265A1 (en) | Indole carboxamides compounds useful as kinase inhibitors | |
TN2017000158A1 (en) | Carbazole derivatives | |
MX2016004030A (en) | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease. | |
MY192354A (en) | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors | |
PH12016500531B1 (en) | Compound inhibiting activities of btk and/or jak3 kinases | |
BR112015020389A8 (en) | carbazole compounds useful as bromodomain inhibitors, their use as well as pharmaceutical composition and product comprising them | |
MX2015016771A (en) | Carbazole carboxamide compounds useful as kinase inhibitors. | |
MX2017005060A (en) | Tricyclic atropisomer compounds. | |
WO2016109217A3 (en) | Btk inhibitors | |
EA201590183A1 (en) | AZAINDOL DERIVATIVES PERFORMING AS PI3K INHIBITORS | |
SG11201806438UA (en) | Fused Pyrazole Derivatives, Preparation Method Thereof, And Use Thereof In Treatment Of Cancers, Inflammation And Immune Diseases | |
PH12019502334A1 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
EA201600636A1 (en) | 2-AMINO-6-METHYL-4,4A, 5,6-TETRAHYDROPYRANO [3,4-D] [1,3] TIASIN-8A (8H) -IL-1,3-TIAZOL-4-IL AMIDY | |
EA201790253A1 (en) | ALDOSTERONSYNTASE INHIBITORS | |
MX2021012543A (en) | Chiral indole compounds and their use. | |
EA202092082A1 (en) | AMINOPYRAZINDIOL COMPOUNDS AS PI3K INHIBITORS |